<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522898</url>
  </required_header>
  <id_info>
    <org_study_id>RAH-HREC-Protocol-#111234</org_study_id>
    <nct_id>NCT01522898</nct_id>
  </id_info>
  <brief_title>Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)</brief_title>
  <acronym>CAAN-AF</acronym>
  <official_title>Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy (CRT) is a treatment for heart failure in patients who also
      suffer from ventricular dyssynchrony, a form of uncoordinated contraction of the ventricle
      (lower pumping chamber of the heart). In the past decade, CRT has become an established
      treatment for heart failure patients who are in normal rhythm, called sinus rhythm. An
      important subset of heart failure patients are those with atrial fibrillation (AF), who make
      up around 1 in 4 HF patients, and are over-represented amongst HF patients with more advanced
      symptoms. In heart failure patients with AF, CRT has proven not to be as effective as in
      sinus rhythm, due to competition between beats generated by the CRT device and beats
      conducted from the heart's own electrical conduction system. In the current study, we aim to
      test the hypothesis that ablating the AV node, which controls electrical conduction from the
      heart's atria (top chamber) to its ventricles (lower chambers), will improve survival and
      heart failure symptoms in CRT patients with co-existent AF. The results are important,
      because they will provide a way of passing on the benefits of CRT, such as improved survival,
      less heart failure symptoms, and better quality of life, to heart failure patients who also
      suffer from AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Cardiac Resynchronization Therapy (CRT) is an established treatment in heart
      failure (HF) patients with ventricular dyssynchrony who remain in sinus rhythm. Available
      clinical data has shown inferior outcomes of CRT in HF patients with co-existent atrial
      fibrillation (AF), who comprise up to 27% of HF patients, and are over-represented in
      advanced HF classes. We hypothesize, based on the results of a systematic review we recently
      published in the Journal of the American College of Cardiology, that AV nodal ablation may
      improve survival, heart failure and functional outcomes in CRT recipients with co-existent
      AF.

      Design: This study will be a multicentre, prospective, randomized controlled trial. Patients
      with ischemic or nonischemic cardiomyopathy heart failure (NYHA II, III or ambulatory class
      IV), left ventricular dysfunction (EF ≤ 35%), prolonged intraventricular conduction (QRS
      duration ≥ 120ms), and persistent or permanent AF will be considered for the study.
      Persistent AF will be defined as patients where obtaining and maintaining sinus rhythm is
      deemed either not worthwhile, or to be ineffective in the long term, or where both the
      patient and the physician accept the presence of AF, where rhythm control intervention is, by
      definition, no longer pursued. Permanent AF is defined as AF where sinus rhythm cannot be
      restored.

      Eligible subjects will be randomized into one of two arms: (1) CRT-D plus AV nodal ablation
      (&quot;AV nodal ablation arm [AVNA]&quot;) or (2) CRT-D alone (&quot;rate control arm&quot;).

      Enrollment: 590 subjects, with 295 subjects in the AV node ablation arm and 295 subjects in
      the control arm, will be enrolled. Study patients will undergo stratified randomization at ≥
      30 days after CRT implant. Participants in will sign informed consent and be screened prior
      to randomisation. After CRT implant, patients will have at least 30 days for optimisation of
      heart failure therapy, prior to randomisation.

      Randomisation: A computer-generated web-based randomisation schedule will be used.
      Randomisation will be stratified by trial centre. Randomisation is considered the trial entry
      point.

      Outcomes: The primary endpoint is a composite of all cause mortality and non-fatal heart
      failure events. Secondary endpoints include all-cause mortality, cardiovascular mortality
      (including classification in terms of suddenness and arrhythmic mechanism by prespecified
      Hinkle-Thaler criteria), non-fatal heart failure events, 6-minute walking test distance,
      quality of life, unplanned hospitalization, and ventricular arrhythmias requiring device
      therapy, inappropriate shocks, cardiovascular MRI prediction of response, percentage pacing
      and prediction of response to therapy, ventricular reverse remodeling.

      Statistical Plan: The study is powered to find a 25% relative reduction in event rate, with
      sample sizes calculated assuming a two-tailed α=0.05,1-β=0.80, and 10% sample size increment
      allow for to drop in the event rate (AV nodal ablation arm), drop out or cross-over
      (feasibly, control to AVNA arm only). It is planned to perform three interim (0.25, 0.5 0.75
      information fractions) and a final analysis requiring 295 patients per arm with a final
      P-value at ≤ 0.045; stopping rules according to the method of O'Brien and Fleming. The
      boundaries (z scores: ±4.332, ±2.963, ±2.359, ±2.014; and nominal P-values: 0.000015, 0.0031,
      0.014, 0.044)) were derived using the statistical package PASS (V12). Outside of these
      defined analyses, the Data Safety Monitoring Board (DSMB) will have access to data reports
      and will be able to stop the trial at any time.

      All analyses will be based on the intention-to-treat principle. The primary (binary)
      mortality-outcome will be analysed using the Cochran-Mantel-Haenszel statistic and logistic
      regression with pre-specified (baseline) covariates. Time-to-event analyses will be initially
      undertaken by the Kaplan-Meier survival analysis approach. Key secondary outcomes such as
      all-cause mortality, cardiovascular mortality, unplanned hospitalisation, and rates of
      ventricular arrhythmia episodes will be analysed using either Cox proportional hazards models
      or Fine and Gray competing risks regression as appropriate. Continuous secondary outcomes
      such as the 6-minute walking distance, Short Form 36 (SF36) scores, Minnesota Living with
      Heart Failure (MLWHF) score will be compared between randomised groups over time using linear
      mixed effects models.

      Significance and Impact: The study will answer a central clinical question directly impacting
      the care of HF patients with AF, and will be expected to change current HF management
      guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality and non-fatal heart failure events</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>This is a composite of all-cause mortality and non-fatal heart failure events. All-cause mortality will be determined by a designated clinical events committee.
Heart Failure events will be documented by clinical data from the hospital In CAAN-AF, a subject will be described as having a &quot;Heart Failure Event&quot; when the subject has symptoms and/or signs consistent with congestive heart failure and:
responsive to parenteral diuretic or inotropic support as an outpatient
responsive to oral or parenteral diuretic or inotropic support during an inpatient stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)f recruitment</time_frame>
    <description>All-cause mortality will be determined after adjudication committee review of clinical records, and death certificate data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Cardiovascular deaths will be classified in terms of suddenness and arrhythmic mechanism according to the Hinkle-Thaler criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Fatal Heart Failure Events</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Heart Failure events will be documented by clinical data from the hospital In CAAN-AF, a subject will be described as having a &quot;Heart Failure Event&quot; when the subject has symptoms and/or signs consistent with congestive heart failure and:
responsive to parenteral diuretic or inotropic support as an outpatient
responsive to oral or parenteral diuretic or inotropic support during an inpatient stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walking distance</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>6-minute walking distance will be measured according to standard criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Quality of life as assessed by the Short Form 36 (SF-36) questionnaire and Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Hospitalization</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Unplanned hospital admissions will be assessed by a combination of patient self-report, hospital record and/or treating physician interrogation. The reason, date and duration of hospitalization will be recorded Planned hospitalizations (hospital visits for elective or planned medical interventions) will excluded from this outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular arrhythmias requiring device therapy</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Ventricular arrhythmias requiring device therapy will be determined by implantable Cardioverter Defibrillator (ICD) interrogation records and clinical records. At each site, the number, duration and type (VT/VF) of device recorded arrhythmias will be recorded, as well as the need for device therapy (anti-tachycardia pacing and/or ICD shocks).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inappropriate shocks</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>The clinical events committee will review clinical records to ascertain if device therapies are appropriate or inappropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular MRI prediction of response</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Cardiovascular MRI will be performed in subjects eligible for this procedure prior to implantation of CRT device, when available. Cardiovascular MRI data will be evaluated for the ability to predict clinical CRT response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Depression will be evaluated in all patients at specified clinical follow-up visits with the Center for Epidemiologic Studies Depression Scale (CES-D questionnaire).</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular reverse remodelling</measure>
    <time_frame>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</time_frame>
    <description>Left ventricular reverse remodeling will be assessed by echocardiographic parameters including left ventricular end systolic volume, left ventricular ejection fraction. An echocardiography core laboratory has been established to process images from individual trial sites for this purpose.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Medical Rate Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV nodal ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AV nodal ablation</intervention_name>
    <description>Percutaneous catheter ablation of the AV node.</description>
    <arm_group_label>AV nodal ablation</arm_group_label>
    <other_name>His Bundle Ablation, AV junctional ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Ventricular Rate Control</intervention_name>
    <description>Ventricular Rate Control with target ventricular rate of 90 beats per minute.</description>
    <arm_group_label>Medical Rate Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Persistent (≥ 1 month) or permanent atrial fibrillation. Persistent AF will be where
             obtaining and maintaining sinus rhythm is deemed either not worthwhile, or to be
             ineffective in the long term, or where both the patient and physician accept the
             presence of AF, where rhythm control intervention is, by definition no longer pursued.
             Permanent AF is defined as atrial fibrillation where sinus rhythm cannot be restored.

          -  NYHA class II , III or ambulatory class IV heart failure

          -  Left Ventricular Ejection Fraction (LVEF) ≤ 35% by objective criteria such as
             echocardiography, or cardiac MRI

          -  QRS duration on 12-lead ECG ≥ 120ms

          -  Able and willing to comply with all pre-, post- and follow-up testing and
             requirements.

        Exclusion Criteria:

          -  age &lt; 18 years

          -  pregnancy

          -  previous AV nodal ablation

          -  Second or third degree AV block

          -  Inability to provide informed consent

          -  life expectancy less than 24 months due to co-morbid illness other than heart failure
             erg cancer, end-stage renal disease, liver failure

          -  Paroxysmal Atrial Fibrillation that self terminates within 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prashanthan Sanders, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Adelaide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prashanthan Sanders, MBBS PhD</last_name>
    <phone>+61-8-8222-2723</phone>
    <email>prash.sanders@adelaide.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anand N Ganesan, MBBS PhD</last_name>
    <phone>+61-8-8222-2723</phone>
    <email>anand.ganesan@adelaide.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wichat Srikusalanukul</last_name>
      <phone>02 6244 4251</phone>
      <email>wichat.srikusalanukul@act.gov.au</email>
    </contact>
    <investigator>
      <last_name>Walter Abhayaratna, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiawen Xue</last_name>
      <phone>02 9767 5624</phone>
      <email>qianwen.xue@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Ray Sy, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maros Elsik, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gordon, MD</last_name>
      <phone>02 4921 4720</phone>
      <email>jhcardiologyresearch@hnehealth.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Malcolm Barlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Wilsmore, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Leitch, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Russell</last_name>
      <phone>02 93820489</phone>
      <email>Anne.Russell@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Singarayar Suresh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Reid</last_name>
      <phone>02 9463 2520</phone>
      <email>emma.reid@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Whalley, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarosh Zaidi</last_name>
      <phone>02 9515 7885</phone>
      <email>sarosh.zaidi@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Raymond Sy, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark McGuire</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley</name>
      <address>
        <city>Murdoch</city>
        <state>Perth, WA</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gill Tulloch</last_name>
      <phone>(08) 61526604</phone>
      <email>gill.tulloch@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Forrest</last_name>
      <phone>(08) 61526604</phone>
      <email>Nicole.forrest@health.wa.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4209</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leeanne Palethorpe</last_name>
      <phone>07 3636 5281</phone>
      <email>leeanne.palethorpe@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Lydia Lilwall</last_name>
      <phone>07 3636 5281</phone>
      <email>lydia.lilwall@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Karin Chia, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Tabrett</last_name>
      <phone>07 3139 6082</phone>
      <email>chantal.tabrett@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Haris Haqqani, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital and Health Service</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Farley</last_name>
      <phone>617 4433 3499</phone>
      <email>Anthony.Farley@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Bobby John</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4213</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Brumby</last_name>
      <phone>(07) 5687 4952</phone>
      <email>Tracey.Brumby@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Lynley Schostakowski</last_name>
      <phone>(07) 5687 4984</phone>
      <email>Lynley.schostakowski@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Hall</last_name>
      <phone>07 3176 5145</phone>
      <email>cindy.hall@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Charmain Seig</last_name>
      <phone>07 3176 5145</phone>
      <email>charmaine.seig@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Kaye, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimie Pauker</last_name>
      <phone>08 8313 9002</phone>
      <email>aimie.pauker@adelaide.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Anna Chua</last_name>
      <phone>08 8313 9000</phone>
      <email>anna.chua@adelaide.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Prashanthan Sanders, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anand N Ganesan, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glenn D Young, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt C Roberts-Thomson, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis H Lau, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Hillock, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Hoffman</last_name>
      <phone>(08) 8182 9439</phone>
    </contact>
    <investigator>
      <last_name>Margaret Arstall, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Wollaston</last_name>
      <phone>08 8204 4440</phone>
      <email>fiona.wollaston2@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Andrew McGavigan, MBChB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Heddle, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cameron Singleton, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy McIntosh</last_name>
      <phone>(03) 6166 8287</phone>
      <email>cathy.mcintosh@ths.tas.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Vicki O'May</last_name>
      <phone>(03) 61668287</phone>
      <email>vicki.omay@ths.tas.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Baldi</last_name>
      <phone>03 9594 4595</phone>
      <email>mauro.baldi@monashhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Wallace Mitchell</last_name>
      <phone>03 9594 4595</phone>
      <email>wendy.wallacemitchell@monashhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeff Alison</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khang Looi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Ryan</last_name>
      <phone>03 4215 1027</phone>
      <email>SUSANRY@barwonhealth.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Toni Shanahan</last_name>
      <phone>03 4215 1027</phone>
      <email>TONIS@barwonhealth.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Perrin, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ord</last_name>
      <phone>03 9496 5973</phone>
      <email>michelle.ord@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>David O'Donnell, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melbourne Private Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Ward</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Kalman, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Azzopardi</last_name>
      <phone>03 9076 3352</phone>
      <email>sonia.azzopardi@bakeridi.edu.au</email>
    </contact>
    <investigator>
      <last_name>Paul Kistler, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justini Mariani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pramila Naidu</last_name>
      <phone>03 9342 8583</phone>
      <email>pramila.naidu@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Jonathan M Kalman, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Walker</last_name>
      <phone>08 6151 0519</phone>
      <email>isabelle.walker@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Paul Stobie, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tze Chung</last_name>
      <phone>(08) 9224 8069</phone>
      <email>tze.chung@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Kim Ireland</last_name>
      <phone>(08) 9224 8069</phone>
      <email>kim.ireland@health.wa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Vince Paul, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Gattorna, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>Martinistr. 52 Gebäude Ost 50, 8. OG, Raum 842</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Heitmann</last_name>
      <phone>+49 (0)40 7410 - 59471</phone>
      <email>k.heitmann@uke.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Willems</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nele Gessler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Arnold</last_name>
      <phone>64 7579 8531</phone>
      <email>wendy.arnold@bopdhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Dean Boddington</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathon Tisch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Fish</last_name>
      <phone>64 9307 4949</phone>
      <email>mfish@adhb.govt.nz</email>
    </contact>
    <contact_backup>
      <last_name>Jan Burd</last_name>
      <phone>64 9307 4949</phone>
      <email>jburd@adhb.govt.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Nigel Lever</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Wanner</last_name>
      <phone>64 7839 7136</phone>
      <email>lizw@cardiotrialswaikato.org.nz</email>
    </contact>
    <investigator>
      <last_name>Martin Stiles, MBChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bronwyn Davies</last_name>
      <phone>64 48060141</phone>
      <email>bronwyn.davies@ccdhb.org.nz</email>
    </contact>
    <contact_backup>
      <last_name>Beverley Beverley.Scott@ccdhb.org.nz</last_name>
      <phone>64 48060141</phone>
    </contact_backup>
    <investigator>
      <last_name>Matthew Webber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>Prashanthan Sanders</investigator_full_name>
    <investigator_title>Director, Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

